Tag
Despite menopause being a universal experience, many physicians lack adequate training in menopause care, resulting in unmet patient needs and increased reliance on unregulated sources. Medical education reforms are essential to close this
This retrospective cohort study indicates that menopausal hormone therapy (MHT) is associated with increased risks of strabismus diagnosis and surgery but not reoperation in menopausal women, revealing significant ocular alignment considera
This study investigates the association between peri- and post-menopausal hormone replacement therapy (HRT) and the risk of voice disorders, revealing transiently increased dysphonia risk within the first nine months but no sustained clinic
A comprehensive longitudinal study reveals that menopausal transition does not significantly alter thyroid function beyond normal aging effects in healthy women, clarifying the interplay between menopause and thyroid health.
Practical, symptom‑focused recommendations for managing menopause in people with cancer—balancing symptom relief with oncologic safety using nonhormonal first-line strategies, selective use of local estrogen, and shared decision making for
This article reviews evidence-based integrative medicine approaches for menopause, including lifestyle, mind-body therapies, nutrition, botanicals, and acupuncture, emphasizing nonhormonal options for symptom relief and health optimization.
Menopause isn't a "stop button" for intimacy, nor is there any medical rule dictating that you must retire your sex life at a certain age. What truly
A comprehensive study reveals initiation rates, duration, and racial disparities in systemic hormone therapy use among menopausal women, emphasizing critical care gaps and the need for equitable interventions.
Hormone therapy initiated within one year after chemoradiotherapy in young patients with locally advanced cervical cancer is associated with reduced metabolic, skeletal, and cerebrovascular risks, and improved survival without increased onc
A contemporary review shows that uterine leiomyomas often persist across menopause, requiring symptom-driven evaluation, structured imaging, and individualized management rather than assumptions of spontaneous regression.
FAERS postmarketing data suggest fezolinetant is associated with an early hepatic adverse event reporting signal, driven mainly by liver enzyme elevations rather than consistent severe clinical liver injury.
A large Australian longitudinal study found that women with both hot flushes and night sweats had slightly higher odds of retirement, suggesting menopausal symptom burden may influence workforce participation.
A large UK Biobank cohort study of 121,017 postmenopausal women reveals that earlier menopause significantly increases risks of multimorbidity progression, with women experiencing premature menopause facing 32% higher risk of developing fir
A longitudinal analysis from the SWAN study indicates that women treated with levothyroxine for hypothyroidism do not face a higher risk of cardiovascular events compared to those without thyroid disease, providing clinical reassurance for
A massive cohort study of 2.2 million women reveals that ovarian cancer risk factors vary significantly by menopausal status and birth year. While early menarche and low parity remain universal risks, the protective benefits of breastfeedin
Updated Cochrane review shows mixed outcomes for long-term hormone therapy in peri- and postmenopausal women.
Elinzanetant, approved in the UK in July 2025 and by the FDA in October 2025, is the first non-hormonal NK1 and NK3 receptor antagonist for moderate-to-severe menopausal vasomotor symptoms, demonstrated effective and safe in pivotal phase 2
OASIS‑3 evaluated once‑daily oral elinzanetant 120 mg vs placebo for 52 weeks in postmenopausal women with moderate–severe vasomotor symptoms. At 12 weeks elinzanetant reduced daily moderate–severe VMS frequency by a least‑squares mean diff
Bayer’s Lynkuet (elinzanetant), a first-in-class dual neurokinin 1 and 3 receptor antagonist, has received FDA approval for treatment of moderate to severe menopausal vasomotor symptoms, demonstrating sustained efficacy and favorable
A comprehensive analysis reveals that menopause does not significantly alter the risk of disability progression in women with relapse-onset multiple sclerosis, underscoring the complexity of reproductive aging’s role in disease trajec
